The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension

The aim of this study was to compare 80 mg telmisartan/5 mg amlodipine/12.5 mg hydrochlorothiazide (T80/A5/H12.5) with 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5) to determine their relative blood pressure (BP) lowering effects in essential hypertensive patients with inadequate control...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension research 2017-01, Vol.40 (1), p.51-60
Main Authors: Higaki, Jitsuo, Komuro, Issei, Shiki, Kosuke, Ugai, Hiroyuki, Taniguchi, Atsushi, Ikeda, Hiroshi, Kuroki, Daisuke, Nishimura, Seiichiro, Ogihara, Toshio
Format: Article
Language:English
Subjects:
Adult
Aged
Amlodipine - administration & dosage
Amlodipine - adverse effects
Amlodipine - therapeutic use
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Benzimidazoles - administration & dosage
Benzimidazoles - adverse effects
Benzimidazoles - therapeutic use
Benzoates - administration & dosage
Benzoates - adverse effects
Benzoates - therapeutic use
Blood Pressure - drug effects
Double-Blind Method
Drug Therapy, Combination
Essential Hypertension
Female
Humans
Hydrochlorothiazide - administration & dosage
Hydrochlorothiazide - adverse effects
Hydrochlorothiazide - therapeutic use
Hypertension - drug therapy
Japan
Male
Middle Aged
Original
Telmisartan
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to compare 80 mg telmisartan/5 mg amlodipine/12.5 mg hydrochlorothiazide (T80/A5/H12.5) with 80 mg telmisartan/12.5 mg hydrochlorothiazide (T80/H12.5) to determine their relative blood pressure (BP) lowering effects in essential hypertensive patients with inadequate control and to evaluate the long-term safety of T80/A5/H12.5 in a 52-week extension period. Patients (n=132) were randomly assigned to receive double-blind treatment with T80/A5/H12.5 or T80/H12.5 for 8 weeks after a 6-week run-in-period of T80/H12.5. All 126 patients who completed the double-blind period entered the 52-week open-label extension and received T80/A5/H12.5. The adjusted mean changes from the reference baseline of the trough-seated systolic and diastolic BP (SBP/DBP) at week 8 were significantly larger in the T80/A5/H12.5 group (-10.6/-8.8 mm Hg) than in the T80/H12.5 group (-2.3/-1.3 mm Hg) (P
ISSN:0916-9636
1348-4214
DOI:10.1038/hr.2016.100